Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Neuronetics commercializes the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) device FDA-cleared for treating major depressive disorder and OCD. The company operates through a capital equipment sales model and recurring revenue from treatment sessions, competing in the $200B+ global depression treatment market with differentiation through non-drug, non-invasive therapy targeting patients who have failed antidepressants.
Neuronetics employs a razor-razorblades model: selling capital equipment at modest margins (estimated 40-50% gross margin on systems) while generating high-margin recurring revenue from proprietary single-use treatment coils required for each patient session. Pricing power derives from FDA clearance, clinical evidence base, and switching costs once providers invest in training and patient protocols. The company targets psychiatrists and mental health facilities, with reimbursement from Medicare (established CPT codes) and commercial insurers driving adoption. Competitive advantages include first-mover status in TMS, extensive clinical data, and an installed base creating network effects through provider familiarity.
NeuroStar system placements per quarter - new installations drive both immediate equipment revenue and future recurring treatment session revenue
Treatment session utilization rates - average sessions per system per month indicates practice adoption and patient throughput
Reimbursement coverage expansions - new insurer coverage decisions or Medicare rate changes directly impact addressable market
Clinical trial results for label expansions - FDA clearances for additional indications (PTSD, anxiety) would significantly expand TAM
Cash burn rate and financing needs - with negative FCF, runway to profitability and dilution risk drive valuation
Reimbursement risk - Medicare or commercial insurers could reduce coverage or reimbursement rates for TMS therapy, directly impacting treatment session economics and provider willingness to invest in systems
Competitive technology displacement - emerging neuromodulation technologies (ketamine therapy, newer TMS protocols, digital therapeutics) could erode market share or commoditize TMS treatment
Regulatory pathway challenges - delays or failures in obtaining FDA clearances for label expansions limit TAM growth and competitive positioning
Established competitors with broader product portfolios (Brainsway, Magstim) and new entrants offering lower-cost TMS alternatives erode pricing power and market share
Pharmaceutical companies developing novel antidepressants or alternative therapies could reduce TMS adoption as second-line treatment option
High debt/equity ratio of 3.32 with negative cash flow creates refinancing risk and potential covenant violations if revenue targets are missed
Negative operating cash flow of $4.6M TTM and FCF yield of -34.6% indicate substantial dilution risk from future equity raises needed to fund operations until profitability
Current ratio of 2.24 provides near-term liquidity buffer, but cash burn rate requires monitoring for going concern risk if capital markets become inaccessible
moderate - Capital equipment purchases by psychiatric practices are somewhat discretionary and sensitive to practice cash flows and financing availability during recessions. However, mental health treatment demand is relatively recession-resistant and may increase during economic stress. The 72% gross margin provides buffer, but negative operating margins create vulnerability to revenue shortfalls.
Rising rates negatively impact the business through multiple channels: (1) higher financing costs for practices purchasing $60K-$80K systems reduce affordability, (2) increased cost of capital compresses valuation multiples for unprofitable growth companies, (3) higher discount rates reduce NPV of future recurring revenue streams. The 3.32 debt/equity ratio indicates material interest expense sensitivity.
Moderate exposure - practice financing availability affects system sales, as many customers use equipment leasing or loans. Tightening credit conditions reduce addressable market. The company's own credit access is critical given negative cash flow and potential need for additional capital raises.
growth - Attracts speculative investors betting on mental health market expansion, TMS adoption acceleration, and path to profitability. The -72.6% one-year return and -61.3% six-month return reflect high-risk, high-reward profile. Not suitable for value or income investors given negative earnings, no dividend, and elevated debt levels. Requires conviction in neuromodulation TAM expansion and company's ability to achieve scale.
high - Small-cap medical device company with $100M market cap, negative profitability, and binary catalysts (FDA decisions, reimbursement changes, clinical trial results) creates significant price volatility. The 72.6% annual decline indicates elevated beta and susceptibility to sector rotation away from unprofitable healthcare growth stocks.
